Post-treatment changes in tumor microenvironment

Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging

Benedicte F. Jordan, Jean-Philippe Galons, Robert J. Gillies

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

One method for noninvasively assessing tumor physiology and metabolism is magnetic resonance imaging (MRI). This chapter presents the potential of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DW-MRI) to monitor post-treatment changes in the tumor microenvironment in both the preclinical and clinical settings. DCE-MRI is widely used in the diagnosis and staging of cancer and is emerging as a promising method for monitoring tumor response to treatment. It is used experimentally to monitor the effectiveness of a variety of treatments, including chemotherapy, radiotherapy, hormonal manipulation, and novel therapeutic approaches, such as anti-angiogenic drugs. Diffusion-weighted MRI can detect tumor response to chemotherapy quantitatively, sensitively, and early in the treatment regimen. While DCE-MRI provides information regarding tumor vasculature, ADCw is sensitive to cellular volume fractions (cellularity). Because they image different markers of response, DCE- and DW-MRI may show differences in amplitude and timing of response. Hence, these techniques are complementary and could be combined in experimental studies. As DCE-MRI is noninvasive, the tumor can be monitored longitudinally over a period of time to study the changes in tumor vascularity occurring during growth and alterations induced by various kinds of therapy. Initial results in the clinic using the low-molecular-weight contrast agent Gd-DTPA indicate that DCE-MRI is useful for both diagnosis and prognosis.

Original languageEnglish (US)
Title of host publicationCancer Imaging
PublisherAcademic Press
Pages235-248
Number of pages14
ISBN (Print)9780123742124
DOIs
StatePublished - 2008

Fingerprint

Diffusion Magnetic Resonance Imaging
Tumor Microenvironment
Magnetic resonance
Tumors
Magnetic resonance imaging
Imaging techniques
Neoplasms
Chemotherapy
Therapeutics
Magnetic Resonance Imaging
Drug Therapy
Gadolinium DTPA
Angiogenesis Inhibitors
Neoplasm Staging
Physiology
Radiotherapy
Contrast Media
Metabolism
Molecular Weight
Volume fraction

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Post-treatment changes in tumor microenvironment : Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging. / Jordan, Benedicte F.; Galons, Jean-Philippe; Gillies, Robert J.

Cancer Imaging. Academic Press, 2008. p. 235-248.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{2f8a3b053e5e4493beb89f89e9e0a39d,
title = "Post-treatment changes in tumor microenvironment: Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging",
abstract = "One method for noninvasively assessing tumor physiology and metabolism is magnetic resonance imaging (MRI). This chapter presents the potential of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DW-MRI) to monitor post-treatment changes in the tumor microenvironment in both the preclinical and clinical settings. DCE-MRI is widely used in the diagnosis and staging of cancer and is emerging as a promising method for monitoring tumor response to treatment. It is used experimentally to monitor the effectiveness of a variety of treatments, including chemotherapy, radiotherapy, hormonal manipulation, and novel therapeutic approaches, such as anti-angiogenic drugs. Diffusion-weighted MRI can detect tumor response to chemotherapy quantitatively, sensitively, and early in the treatment regimen. While DCE-MRI provides information regarding tumor vasculature, ADCw is sensitive to cellular volume fractions (cellularity). Because they image different markers of response, DCE- and DW-MRI may show differences in amplitude and timing of response. Hence, these techniques are complementary and could be combined in experimental studies. As DCE-MRI is noninvasive, the tumor can be monitored longitudinally over a period of time to study the changes in tumor vascularity occurring during growth and alterations induced by various kinds of therapy. Initial results in the clinic using the low-molecular-weight contrast agent Gd-DTPA indicate that DCE-MRI is useful for both diagnosis and prognosis.",
author = "Jordan, {Benedicte F.} and Jean-Philippe Galons and Gillies, {Robert J.}",
year = "2008",
doi = "10.1016/B978-012374212-4.50094-8",
language = "English (US)",
isbn = "9780123742124",
pages = "235--248",
booktitle = "Cancer Imaging",
publisher = "Academic Press",

}

TY - CHAP

T1 - Post-treatment changes in tumor microenvironment

T2 - Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging

AU - Jordan, Benedicte F.

AU - Galons, Jean-Philippe

AU - Gillies, Robert J.

PY - 2008

Y1 - 2008

N2 - One method for noninvasively assessing tumor physiology and metabolism is magnetic resonance imaging (MRI). This chapter presents the potential of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DW-MRI) to monitor post-treatment changes in the tumor microenvironment in both the preclinical and clinical settings. DCE-MRI is widely used in the diagnosis and staging of cancer and is emerging as a promising method for monitoring tumor response to treatment. It is used experimentally to monitor the effectiveness of a variety of treatments, including chemotherapy, radiotherapy, hormonal manipulation, and novel therapeutic approaches, such as anti-angiogenic drugs. Diffusion-weighted MRI can detect tumor response to chemotherapy quantitatively, sensitively, and early in the treatment regimen. While DCE-MRI provides information regarding tumor vasculature, ADCw is sensitive to cellular volume fractions (cellularity). Because they image different markers of response, DCE- and DW-MRI may show differences in amplitude and timing of response. Hence, these techniques are complementary and could be combined in experimental studies. As DCE-MRI is noninvasive, the tumor can be monitored longitudinally over a period of time to study the changes in tumor vascularity occurring during growth and alterations induced by various kinds of therapy. Initial results in the clinic using the low-molecular-weight contrast agent Gd-DTPA indicate that DCE-MRI is useful for both diagnosis and prognosis.

AB - One method for noninvasively assessing tumor physiology and metabolism is magnetic resonance imaging (MRI). This chapter presents the potential of dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted MRI (DW-MRI) to monitor post-treatment changes in the tumor microenvironment in both the preclinical and clinical settings. DCE-MRI is widely used in the diagnosis and staging of cancer and is emerging as a promising method for monitoring tumor response to treatment. It is used experimentally to monitor the effectiveness of a variety of treatments, including chemotherapy, radiotherapy, hormonal manipulation, and novel therapeutic approaches, such as anti-angiogenic drugs. Diffusion-weighted MRI can detect tumor response to chemotherapy quantitatively, sensitively, and early in the treatment regimen. While DCE-MRI provides information regarding tumor vasculature, ADCw is sensitive to cellular volume fractions (cellularity). Because they image different markers of response, DCE- and DW-MRI may show differences in amplitude and timing of response. Hence, these techniques are complementary and could be combined in experimental studies. As DCE-MRI is noninvasive, the tumor can be monitored longitudinally over a period of time to study the changes in tumor vascularity occurring during growth and alterations induced by various kinds of therapy. Initial results in the clinic using the low-molecular-weight contrast agent Gd-DTPA indicate that DCE-MRI is useful for both diagnosis and prognosis.

UR - http://www.scopus.com/inward/record.url?scp=78650639672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650639672&partnerID=8YFLogxK

U2 - 10.1016/B978-012374212-4.50094-8

DO - 10.1016/B978-012374212-4.50094-8

M3 - Chapter

SN - 9780123742124

SP - 235

EP - 248

BT - Cancer Imaging

PB - Academic Press

ER -